Literature DB >> 11245059

Lack of evidence of active lytic replication of Epstein-Barr and cytomegaloviruses in patients with systemic lupus erythematosus.

C S Lau1, K Y Yuen, K H Chan, R W Wong.   

Abstract

OBJECTIVES: Systemic lupus erythematosus (SLE) is a multifactorial disease. Environmental factors such as viral infection(s) have been proposed as pathaetiological factors. There are particular interests in studying lymphotropic viruses such as the Epstein-Barr virus (EBV) and cytomegalovirus (CMV). Although previous case reports and in vitro studies suggested that they may have a role, there is no direct evidence that onset of SLE or disease exacerbation is associated with active infection by these viruses. Using the very sensitive polymerase chain reaction (PCR) technique, we tried to find out evidence of active replication of these viruses in patients with SLE.
METHODS: Thirty-four patients with SLE were compared with matched normal controls. Eleven patients were newly diagnosed to have SLE and 18 of the 34 patients had active disease as determined by a SLE Disease Activity Index (SLEDAI) score of > or = 10 at the time of study.
RESULTS: Our results showed no evidence of active replication or reactivation of EBV in the leucocytes amongst the newly diagnosed SLE patients, established SLE patients, patients with SLEDAI > or = 10, patients with SLEDAI < 10, and control subjects. There was no evidence of CMV infection in any of the subjects studied. The IgG and IgA responses against EBV early antigen (EA) and viral capsid antigen (VCA) were also studied. The IgG and IgA responses against VCA of EBV were increased in patients with SLE when compared with controls. However, there were no differences in these responses among different subgroups of patients. The mechanism of these responses was not apparent but may represent non-specific hyperimmune responses in these patients. There were no differences in the titre of IgG and IgA against EBV EA between the patient groups and controls.
CONCLUSION: There is no direct evidence that either EBV or CMV plays a direct role in the onset and/or exacerbation of SLE.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 11245059

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  7 in total

1.  Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study.

Authors:  Bahar Artım Esen; Gülden Yılmaz; Sami Uzun; Melda Ozdamar; Alper Aksözek; Sevil Kamalı; Salih Türkoğlu; Ahmet Gül; Lale Ocal; Orhan Aral; Murat Inanç
Journal:  Rheumatol Int       Date:  2010-07-27       Impact factor: 2.631

2.  Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan.

Authors:  Shan-Fu Yu; Huei-Chuin Wu; Wen-Chan Tsai; Jeng-Hsien Yen; Wen Chiang; Chung-Yee Yuo; Sheng-Nan Lu; Lien-Chai Chiang; Chung-Jen Chen
Journal:  Med Microbiol Immunol       Date:  2004-09-17       Impact factor: 3.402

Review 3.  Epstein-Barr virus and systemic lupus erythematosus.

Authors:  Anette Holck Draborg; Karen Duus; Gunnar Houen
Journal:  Clin Dev Immunol       Date:  2012-07-03

Review 4.  Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus.

Authors:  Peter Hanlon; Alison Avenell; Lorna Aucott; Mark A Vickers
Journal:  Arthritis Res Ther       Date:  2014-01-06       Impact factor: 5.156

5.  Altered Olfactory Function in Patients with Systemic Lupus Erythematosus.

Authors:  Qilin Chen; Feng Qiu; Huaxiang Liu; Xingfu Li; Jie Li
Journal:  Med Sci Monit       Date:  2019-08-09

Review 6.  Epstein-Barr virus in systemic autoimmune diseases.

Authors:  Anette Holck Draborg; Karen Duus; Gunnar Houen
Journal:  Clin Dev Immunol       Date:  2013-08-24

7.  The risk of systemic lupus erythematosus associated with Epstein-Barr virus infection: a systematic review and meta-analysis.

Authors:  Zhao-Xia Li; Shan Zeng; Hui-Xia Wu; Yi Zhou
Journal:  Clin Exp Med       Date:  2018-10-25       Impact factor: 3.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.